Gene lists related to cancer immunotherapy
Last updated: September 10th, 2024
Sources:
Methodology:
- Intersection of genes in CTpedia which have at least one tissue antibody staining in HPA, keeping only expression in testis and placenta.
Last updated: July 21st, 2018
Sources:
- Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance:
- LMP2/7
- peptide transporters TAP1/2
- chaperones calreticulin, calnexin, ERP57, and tapasin
- IFR-1 and NLRC5
- Expression of Antigen Processing and Presenting Molecules in Brain Metastasis of Breast Cancer
- "β2-microgloblin, transporter associated with antigen processing (TAP) 1, TAP2 and calnexin are down-regulated in brain lesions compared with unpaired breast lesions"
- NLRC5/MHC class I transactivator is a target for immune evasion in cancer
- TAPBPR: a new player in the MHC class I presentation pathway
Last updated: July 21st, 2018
Sources:
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- "JAK1/JAK2-STAT1/STAT2/STAT3-IRF1 axis primarily regulates PD-L1 expression, with IRF1 binding to its promoter"
- "PD-L2 responded equally to interferon beta and gamma and is regulated through both IRF1 and STAT3, which bind to the PD-L2 promoter"
- "the suppressor of cytokine signaling protein family (SOCS; mostly SOCS1 and SOCS3) are involved in negative feedback regulation of cytokines that signal mainly through JAK2 binding, thereby modulating the activity of both STAT1 and STAT3"
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- "resistance-associated loss-of-function mutations in the genes encoding interferon-receptor–associated Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), concurrent with deletion of the wild-type allele"
- SOCS, inflammation, and cancer
- "Abnormal expression of SOCS1 and SOCS3 in cancer cells has been reported in human carcinoma associated with dysregulation of signals from cytokine receptors"
Last updated: July 21st, 2018
Cancer genes and recurrent mutations extract from Comprehensive Characterization of Cancer Driver Genes and Mutations.
Genes extracted from Table S1 into cancer-driver-genes.csv
. Mutations extracted from Table S4 into cancer-driver-variants.csv
.
Both datasets were annotated with Ensembl IDs using Ensembl release 92.